Key result
Dyslipidemia linked to ~65% higher serum Thrombospondin-1 alongside elevated Tenascin-C.
Why the study?
Although tenascin-c and thrombospondin-1 are identified as biomarkers of cardiovascular disease, their levels and utility specifically in patients with dyslipidemia required evaluation.
Do serum Tenascin-c and Thrombospondin-1 levels serve as sensitive and specific biomarkers for cardiovascular disease in patients with dyslipidemia compared to healthy controls?
Case-Control (n=90)
Yes
Do serum Tenascin-c and Thrombospondin-1 levels serve as sensitive and specific biomarkers for cardiovascular disease in patients with dyslipidemia compared to healthy controls?
Serum Thrombospondin-1 and Tenascin-C are significantly elevated in patients with dyslipidemia and correlate with atherogenic lipid profiles, with Thrombospondin-1 showing high sensitivity and specificity as a potential early biomarker for cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Supports further biomarker evaluation in dyslipidemia; leaves open prospective validation for cardiovascular risk prediction.
This study aimed to evaluate Tenascin-c (TN-C) and thrombospondin-1 (TSP-1) levels in patients with dyslipidemia concerning cardiovascular disease. Numerous studies have identified TN-C and TSP-1 as biomarkers of cardiovascular disease. The study included 45 dyslipidemia patients and 45 healthy controls. The results showed significantly higher levels of Tenascin-C -C and Thrombospondin-1 in patients compared to control group, with P<0.001. Additionally, mean levels of serum Ca, serum ionized Ca, and vitamin D3 were significantly decreased P<0.001 in patients compared to controls. Positive correlation was found between Tenascin-c and Thrombospondin -1 with cholesterol and LDL, r=0.532, r=0.600, respectively, with P<0.001, while negative correlations were observed between both Tenascin-c and Thrombospondin -1with HDL, Ca, ion Ca, and vitD3 with P<0.001. The level of Tenascin-c was positively correlated with the level of VLDL. Finally, the study found that TSP-1 was a more sensitive and specific biomarker than TN-C for early diagnosis of cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Hassan et al. (2026) conducted a case-control in Dyslipidemia (n=90). Dyslipidemia (evaluated for serum Thrombospondin-1 and Tenascin-C levels) vs. Healthy controls was evaluated on Serum Thrombospondin-1 (TSP-1) concentration (ng/ml) and diagnostic performance (AUC 0.950, 95% CI 0.890 - 0.988, p=<0.001). Dyslipidemia patients had significantly higher serum Thrombospondin-1 (123.46 vs 74.71 ng/ml, p<0.001) and Tenascin-C (15.53 vs 7.26 ng/ml, p<0.001) levels compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: